Foundayo vs Wegovy vs Zepbound: A 2026 GLP-1 Drug Comparison
Key Takeaways
- Efficacy: Foundayo (orforglipron) led to an average weight loss of 11-12% in its key clinical trial, a clinically significant result that is modestly lower than the ~15% seen with Wegovy (semaglutide) and ~20-21% with Zepbound (tirzepatide).
- Unmatched Convenience: Foundayo is the first non-peptide, small-molecule oral GLP-1 agonist. This allows for simple once-daily dosing without the fasting or water restrictions required by oral semaglutide.
- Responder Rates: In the ATTAIN-1 trial, approximately 36-40% of participants taking the highest dose of orforglipron lost at least 15% of their body weight, compared to just 6% on placebo.
- Safety Profile: Foundayo’s side effects are consistent with the GLP-1 class. The most common are gastrointestinal, with nausea affecting 29-36% of users, leading to a discontinuation rate of 5-10% in clinical trials.
GLP-1 receptor agonists have completely changed how we approach medical weight management. And the recent FDA approval of Eli Lilly’s Foundayo (orforglipron) is a big deal. As the very first once-daily, non-peptide oral GLP-1 tablet, Foundayo offers a new, easy way for patients with obesity to get treatment. But here’s the thing—we already have incredibly effective options like Wegovy (semaglutide) and Zepbound (tirzepatide). So, for both my patients and me as a clinician, a big question comes up: Where exactly does this new medication fit in? In this article, I’m going to give you my take, a balanced look at orforglipron vs semaglutide and tirzepatide. We’ll weigh the pros and cons—efficacy, how easy they are to use, and side effects—to help us all make better treatment choices in 2026.
Efficacy Showdown: Comparing Weight Loss Percentages
When I’m looking at any new weight loss medication, the first thing I check is how well it actually works. We need to see the numbers. The data from big clinical trials really helps us understand what my patients can realistically expect. For Foundayo (orforglipron), the 72-week ATTAIN-1 trial showed participants on the highest dose (36 mg) lost, on average, between 11.2% and 12.4% of their body weight. Imagine a 250-pound person; that’s roughly 27-31 pounds lost. And, about 55-60% of those on orforglipron lost at least 10% of their body weight. That’s a threshold I consider truly meaningful for improving someone’s heart and metabolic health.
So, how does Foundayo measure up against its rivals? The figures paint a clear picture. Injectable semaglutide (Wegovy), studied in the STEP-1 trial, typically led to about 15% average weight loss over a similar period. The high-dose oral version of semaglutide, from the OASIS-4 trial, showed similar, maybe even slightly better, results at around 15-17%. But at the top of the heap for weight loss is injectable tirzepatide (Zepbound). This one is a dual GIP/GLP-1 agonist, and in the SURMOUNT-1 trial, it delivered an impressive 20-21% average weight loss. Yes, Foundayo’s ~12% loss is a bit lower numerically. But let me be direct about this: it’s still a very effective intervention, far better than placebo (~2.1% loss), and it easily beats the older anti-obesity medications.
The Convenience Factor: Oral Pills vs. Injections
Foundayo’s biggest strength, to me, is how you take it and its unique structure. It’s a true “small-molecule” drug, not a peptide. This chemical difference is incredibly important. See, we do have an oral version of semaglutide, but it’s a peptide. That means it needs a special delivery system just to survive stomach acid. And that leads to some really strict rules for taking it: empty stomach, small amount of water, and then you have to wait a full 30 minutes before eating, drinking, or taking anything else. For many of my patients, sticking to that rigid morning routine is a real challenge. It can make them quit altogether.
Foundayo, on the other hand, just wipes out that whole problem. Since it’s not a peptide, your body absorbs it easily. You can take it once a day, any time you want, with or without food. This kind of effortless simplicity is a total game-changer for oral obesity treatment. And what about needles? For patients who dread shots, both Wegovy and Zepbound can be a barrier with their once-weekly subcutaneous injections. I’ve seen patients adapt well to injections, but that psychological hurdle is absolutely real. The choice between a simple daily pill and a weekly shot is a big part of our shared decision-making process. Foundayo simply gives us the most convenient oral choice out there.
Now, about the side effects—A Head-to-Head Look at Safety
No medication is perfect, and the GLP-1 receptor agonist class, as a whole, has a pretty well-known safety profile. Most of the issues are gastrointestinal (GI). Why? Because these drugs slow down how fast your stomach empties. Foundayo is no different. In the ATTAIN-1 trial, the most common problems were nausea (reported by 29-36% of Foundayo users compared to ~10% on placebo), diarrhea, and vomiting. These side effects are usually mild to moderate. And they tend to get better over time as your body adjusts. But they were serious enough to make 5-10% of participants stop the medication, compared to 3% in the placebo group.
This side effect picture is quite similar to what we see with semaglutide and tirzepatide. GI issues are the most frequent complaints across the board. The key to managing these effects, for all GLP-1 drugs, is a slow, careful dose-escalation schedule. And just like its cousins, Foundayo isn’t for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). I also advise caution for anyone with a history of pancreatitis or severe gallbladder disease. So, Foundayo doesn’t really introduce any new or surprising safety signals. It fits right in with what we already expect from this class of medications.
Comparison Table: Foundayo vs. Wegovy vs. Zepbound in 2026
To help bring this all together, here’s a quick side-by-side comparison of the top GLP-1-based medications for long-term weight management.
| Feature | Foundayo (orforglipron) | Wegovy (semaglutide) | Zepbound (tirzepatide) |
|---|---|---|---|
| Route | Once-Daily Oral Tablet | Once-Weekly Injection (or Daily Oral) | Once-Weekly Injection |
| Fasting Required? | No | Yes (for oral version only) | No |
| Mechanism | GLP-1 Agonist | GLP-1 Agonist | Dual GIP/GLP-1 Agonist |
| Avg. Weight Loss (~72 wks) | ~11-12% | ~15-17% | ~20-21% |
| Common Side Effects | Nausea (~29-36%), diarrhoea, vomiting | Nausea, diarrhoea, vomiting | Nausea, diarrhoea, vomiting |
| Key Advantage | Maximum oral convenience | Proven efficacy, oral/injectable options | Highest available efficacy |
Physician’s Verdict: How to Choose the Right GLP-1 in 2026
In my clinical experience, the “best” weight loss medication is always the one a patient can actually take consistently and tolerate well, while still getting results that make a real difference. Foundayo’s arrival truly adds to our treatment options. It allows us to create even more personalized treatment plans. So, how do we decide between orforglipron vs semaglutide or tirzepatide? It absolutely needs to be a conversation, a shared decision.
Here is a framework for that conversation:
- For the “Maximum Efficacy” Patient: If someone is looking for the absolute most weight loss possible and is fine with weekly injections, they’ll probably still lean towards Zepbound (tirzepatide). Its ~20-21% average weight loss is just unmatched right now.
- For the “Convenience-First” Patient: Foundayo (orforglipron) is the clear winner for anyone who puts simplicity first. This means patients with a strong fear of needles, or those who just can’t stick to the strict fasting rules of oral semaglutide. For this group, giving up a few percentage points of weight loss for the sheer ease of a simple daily pill is definitely a worthwhile trade-off.
- For the “Balanced Approach” Patient: Wegovy (semaglutide) sits comfortably in the middle. It offers better weight loss than Foundayo. And it gives patients a choice: a convenient once-weekly injection, or a daily oral pill for those who can manage the fasting requirements.
Ultimately, I see Foundayo’s introduction as fantastic news for patients. It gives us a strong, incredibly convenient oral choice. This matters because it will improve access and help more people stick with their treatment. While it might not deliver the highest weight loss seen with injectable tirzepatide, its solid ~12% weight loss and user-friendly design make it a powerful new tool in our efforts against obesity.
Sources
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine, 2025. PMID: 40960239. doi:10.1056/NEJMoa2511774
- Santulli G. From needles to pills: oral GLP-1 therapy enters the obesity arena. Cardiovascular Diabetology Endocrinology Reports, 2025. PMID: 41053816. doi:10.1186/s40842-025-00245-5
- Xie Z, Zheng G, Liang Z, et al. Seven GLP-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism, 2024. PMID: 39305981. doi:10.1016/j.metabol.2024.156038
- Kokkorakis M, Chakhtoura M, Rhayem C, et al. Emerging pharmacotherapies for obesity: A systematic review. Pharmacological Reviews, 2025. PMID: 39952695. doi:10.1124/pharmrev.123.001045
This is not personal medical advice. See our medical disclaimer and editorial standards.
Licensed physician and clinical AI specialist. Founder and Editor-in-Chief of ZayedMD, a physician-led medical publication covering clinical AI, neurology, metabolic health, and evidence-based patient guidance.
